{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling in tumors",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units): 3.1 vs 1.0",
          "line_ref": "L31"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling",
          "line_ref": "L42"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings"
    },
    {
      "claim_id": "C02",
      "claim": "Interferon-associated antigen processing and presentation pathways increase, leading to a broader peptide repertoire on MHC-I",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome: 62.3% vs 37.3%",
          "line_ref": "L28"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome: 40.6% vs 20.6%",
          "line_ref": "L29"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors"
    },
    {
      "claim_id": "C03",
      "claim": "PD-L1 pathway activity increases after intratumoral mRNA vaccination, creating a rationale for combining with checkpoint blockade",
      "strength": "strong",
      "evidence": [
        {
          "quote": "PD-L1 expression fold-change in tumor tissue: 2.4x vs 1.0x",
          "line_ref": "L32"
        },
        {
          "quote": "PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade",
          "line_ref": "L45"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings"
    },
    {
      "claim_id": "C04",
      "claim": "Combined mRNA vaccination and checkpoint blockade intervention improves tumor control in mice and is associated with better outcomes in vaccinated patients receiving ICI treatment",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value: p=0.01",
          "line_ref": "L30"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort",
          "line_ref": "L46"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely and tumor-type mix and treatment-history heterogeneity limit direct causal interpretation"
    },
    {
      "claim_id": "C05",
      "claim": "Type I interferon signaling is essential for the sensitization effect, as blocking IFNAR1 eliminates the benefit",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit",
          "line_ref": "L39"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling",
          "line_ref": "L42"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors"
    }
  ]
}